Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04265534
Title KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Calithera Biosciences, Inc
Indications

lung non-squamous non-small cell carcinoma

Therapies

Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat

Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST